Mirum Pharmaceuticals, Inc. Common Stock
Follow $MIRM
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $MIRM by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is MIRM moving today?
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
MIRM overview
Related filings and maps
Congress activity in MIRM
No receipt-qualified Congressional disclosure is present for MIRM in the cached public ledger.
MIRM contract awards, year to date.
Public federal awards linked to this ticker.
MIRM lobbying filings, year to date.
Registered lobbying filings matched to Mirum Pharmaceuticals, Inc. Common Stock.